Hybio Pharmaceutical released its 2026 interim report, with net profit attributable to the parent company of 237 million yuan. The company's total operating revenue was 688 million yuan, and net cash inflow from operating activities was 305 million yuan. The latest gross margin was 62.91 percent, down 1.98 percentage points from the previous quarter, and the latest return on equity was 27.84 percent. Diluted earnings per share were 0.27 yuan, and the asset-liability ratio was 75.65 percent.
Hybio PharmaceuticalCompany reports net profit of 237 million yuan in interim report.
